{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:29:54Z","timestamp":1790094594478,"version":"4.0.1"},"reference-count":29,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,8,7]],"date-time":"2013-08-07T00:00:00Z","timestamp":1375833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2013,9]]},"abstract":"\n \n \n To review the process and rationale for the\n A<\/jats:styled-content>\n merican\n U<\/jats:styled-content>\n rological\n A<\/jats:styled-content>\n ssociation (\n AUA<\/jats:styled-content>\n ) guideline on prostate cancer detection. The\n AUA<\/jats:styled-content>\n guideline on detection of prostate cancer involved a systematic literature review of >300 studies that evaluated outcomes important to patients (prostate cancer, incidence\/mortality, health\u2010related quality of life, diagnostic accuracy and harms of testing). A multidisciplinary panel interpreted the evidence and formulated statements to assist the urologist and the asymptomatic average\u2010risk man in decision\u2010making about prostate cancer detection. Other than prostate\u2010specific antigen (\n PSA<\/jats:styled-content>\n )\u2010based prostate cancer screening, there was no evidence to address the outcomes of interest to patients. The strongest evidence that benefits may outweigh harms was in men aged 55\u201369 years undergoing\n PSA<\/jats:styled-content>\n \u2010based screening. This led the panel to recommend shared decision\u2010making for these men at average risk, but recommend against routine screening for other age groups at average risk. Further, to reduce the harms associated with screening (false positive tests, over diagnosis, over treatment), the panel recommended against annual screening for those who choose to be screened. A panel under the auspices of the\n AUA<\/jats:styled-content>\n recommended shared decision\u2010making for the average risk asymptomatic man aged 55\u201369 years considering\n PSA<\/jats:styled-content>\n \u2010based screening for prostate cancer detection.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/bju.12318","type":"journal-article","created":{"date-parts":[[2013,6,18]],"date-time":"2013-06-18T07:23:19Z","timestamp":1371540199000},"page":"543-547","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":107,"title":["A<\/scp>\n merican\n U<\/scp>\n rological\n A<\/scp>\n ssociation (\n AUA<\/scp>\n ) Guideline on prostate cancer detection: process and rationale"],"prefix":"10.1111","volume":"112","author":[{"given":"H. Ballentine","family":"Carter","sequence":"first","affiliation":[{"name":"The Johns Hopkins University School of Medicine Department of Urology The James Buchanan Brady Urological Institute Johns Hopkins Hospital Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,8,7]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-011-0656-5"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.156703"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08729.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-2-201207170-00459"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.07.093"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.04.119"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/691380"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-012-0824-2"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810696"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810084"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.282"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25568"},{"key":"e_1_2_6_14_1","unstructured":"The Surveillance Epidemiology and End Results (SEER) Program of the National Cancer Institute. Fast Stats. Available at:http:\/\/seer.cancer.gov\/faststats. Accessed 3 June 2013"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-09-1251"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113135"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70146-7"},{"key":"e_1_2_6_18_1","unstructured":"GLOBOCAN: prostate cancer incidence and mortality worldwide in 2008: summary. GLOBOCAN (IARC) Section of Cancer Information 2008. Available at:http:\/\/globocan.iarc.fr\/factsheets\/cancers\/prostate.asp. Accessed June 2013"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt038"},{"key":"e_1_2_6_20_1","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jama.1997.03540420052029","article-title":"Recommended prostate\u2010specific antigen testing intervals for detection of curable prostate cancer","volume":"277","author":"Carter HB","year":"1997","journal-title":"JAMA"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00003"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01304-8"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.16.1857"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c4521"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-10-0718"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113162"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011967"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.002"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.11.117"},{"key":"e_1_2_6_30_1","first-page":"1","article-title":"Guideline promises to end twenty\u2010year war over mass screening for prostate cancer","volume":"39","author":"Brawley OW","year":"2013","journal-title":"Cancer Lett"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.12318","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.12318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:07:02Z","timestamp":1761761222000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.12318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,7]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1111\/bju.12318"],"URL":"https:\/\/doi.org\/10.1111\/bju.12318","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,7]]},"assertion":[{"value":"2013-08-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}